1. Medicines
  2. Cardio-Metabolic
  3. ENTRESTO® (sacubitril/valsartan)
  4. Clinical evidence: efficacy and safety

Prescribing information

 

Clinical evidence: efficacy and safety

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

There’s a wealth of data supporting the use of Entresto in your
chronic HFrEF patients1–7

Make Entresto your first choice, wherever your patients are in their chronic HFrEF journey1–7

 Paradigm-hf1  Pioneer-hf2  Transition3,4  Prove-hf5  Evaluate-hf6

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.7

HFrEF, heart failure with reduced ejection fraction.

References

  1. McMurray JJV et al. N Engl J Med 2014; 371:993–1004.
  2. Velazquez EJ et al. N Engl J Med 2019; 380:539–548.
  3. Pascual-Figal D et al. ESC Heart Fail 2018; 5:327–336.
  4. Wachter R et al. Eur J Heart Fail 2019; 21:998–1007.
  5. Januzzi JL Jr et al. JAMA 2019; 322:1085–1095 plus supplementary info.
  6. Desai AS et al. JAMA 2019; 322:1077–1084 plus supplementary info.
  7. Entresto Summary of Product Characteristics, 2020.
Rate this content: 
No votes yet
ENT20-C046b(1) July 2020.
Cardio-metabolic
Article
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]